10/711513 Structure search

```
=> d que stat
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L2             8 SEA FILE=REGISTRY SSS FUL L1
L3             8 SEA L2
L4             8 DUP REM L3 (0 DUPLICATES REMOVED)


=> d his

     (FILE 'HOME' ENTERED AT 17:35:40 ON 26 JAN 2006)

     FILE 'REGISTRY' ENTERED AT 17:35:54 ON 26 JAN 2006
L1                STRUCTURE UPLOADED
L2             8 S L1 FULL

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 17:36:52 ON 26 JAN 2006
L3             8 S L2
L4             8 DUP REM L3 (0 DUPLICATES REMOVED)

=>
```

10/811513 Reg # search

```
=> d his

     (FILE 'HOME' ENTERED AT 17:44:04 ON 26 JAN 2006)

     FILE 'REGISTRY' ENTERED AT 17:44:44 ON 26 JAN 2006
L1             1 S 283173-50-2/RN

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 17:45:32 ON 26 JAN 2006
L2             8 S L1
L3             7 S L2 AND CANCER
L4             1 S L3 AND IRENOTECAN
L5             1 S L3 AND TEMOZOLAMIDE
L6             2 S L3 AND DACARBAZINE
L7             7 DUP REM L3 (0 DUPLICATES REMOVED)
L8             7 S L3-L6
L9             7 DUP REM L8 (0 DUPLICATES REMOVED)
```

10/811513

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTAAAL1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS	4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS	5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS	6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS	7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS	8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	12	JAN 17	IPC 8 in the WPI family of databases including WPIFV

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:44:04 ON 26 JAN 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:44:44 ON 26 JAN 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JAN 2006 HIGHEST RN 872674-04-9
DICTIONARY FILE UPDATES: 25 JAN 2006 HIGHEST RN 872674-04-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> s 283173-50-2/rn
L1            1 283173-50-2/RN

=> d L1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   283173-50-2  REGISTRY
ED   Entered STN:  04 Aug 2000
CN   6H-Azepino[5,4,3-cd]indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-[4-
     [(methylamino)methyl]phenyl]- (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C19 H18 F N3 O
CI   COM
SR   CA
LC   STN Files:   CA, CAPLUS, IMSDRUGNEWS, IMSRESEARCH, TOXCENTER, USPAT2,
       USPATFULL
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> file hcaplus uspatful pubmed
'PUBMED' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):ignore
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       2.34       2.55

FILE 'HCAPLUS' ENTERED AT 17:45:32 ON 26 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:45:32 ON 26 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s L1
L2            8 L1

=> s L2 and cancer
L3            7 L2 AND CANCER

=> s L3 and irenotecan
L4            1 L3 AND IRENOTECAN

=> s L3 and temozolamide
L5            1 L3 AND TEMOZOLAMIDE

=> s L3 and dacarbazine
L6            2 L3 AND DACARBAZINE

=> d L6 1-2 ibib abs hitstr

L6   ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:857605  HCAPLUS
DOCUMENT NUMBER:          141:325793
TITLE:                    Poly(ADP-ribose) polymerase (PARP) inhibitor
```

8-fluoro-2-(4-methylaminomethylphenyl)-1,3,4,5-tetrahydroazepino[5,4,3-cd]indol-6-one salts for therapeutic use

INVENTOR(S): Canan-Koch, Stacie Sara; Chu, Jan-Jon; Liu, Jia; Matthews, Jean Joo

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087713	A1	20041014	WO 2004-IB915	20040319
WO 2004087713	C1	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2520997	AA	20041014	CA 2004-2520997	20040319
EP 1611137	A1	20060104	EP 2004-721967	20040319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
NL 1025842	A1	20041001	NL 2004-1025842	20040329
US 2004248879	A1	20041209	US 2004-811513	20040329

PRIORITY APPLN. INFO.: US 2003-459433P P 20030331
WO 2004-IB915 W 20040319

AB Pharmaceutically acceptable salts of the title compound are PARP inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As **cancer** therapeutics, the compds. of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation. Preparation of a variety of salts of the title compound is included.

IT **283173-50-2**
RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(PARP inhibitor tetrahydroazepinoindolone derivative salts for therapeutic use)

RN 283173-50-2 HCAPLUS
CN 6H-Azepino[5,4,3-cd]indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 USPATFULL on STN
ACCESSION NUMBER: 2004:315203 USPATFULL
TITLE: Salts of tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Canan-Koch, Stacie, La Jolla, CA, UNITED STATES
Chu, Jan-Jon, Carlsbad, CA, UNITED STATES
Liu, Jia, La Jolla, CA, UNITED STATES
Matthews, Jean, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004248879	A1	20041209	
APPLICATION INFO.:	US 2004-811513	A1	20040329	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-459433P	20030331	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AGOURON PHARMACEUTICALS, INC., 10350 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutically acceptable salts of compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **283173-50-2**
(PARP inhibitor tetrahydroazepinoindolone derivative salts for therapeutic use)
RN 283173-50-2 USPATFULL
CN 6H-Azepino[5,4,3-cd]indol-6-one, 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)




```
=> d his

     (FILE 'HOME' ENTERED AT 17:44:04 ON 26 JAN 2006)

     FILE 'REGISTRY' ENTERED AT 17:44:44 ON 26 JAN 2006
L1            1 S 283173-50-2/RN

     FILE 'HCAPLUS, USPATFULL' ENTERED AT 17:45:32 ON 26 JAN 2006
L2            8 S L1
L3            7 S L2 AND CANCER
L4            1 S L3 AND IRENOTECAN
L5            1 S L3 AND TEMOZOLAMIDE
L6            2 S L3 AND DACARBAZINE

=> L3 dup rem
L3 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> dup rem L3
PROCESSING COMPLETED FOR L3
L7            7 DUP REM L3 (0 DUPLICATES REMOVED)

=> d L3 1-7 ibib abs

L3   ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:120932  HCAPLUS
DOCUMENT NUMBER:          142:212321
TITLE:                    Tricyclic lactam indole derivatives and tricyclic
                          lactam benzimidazole derivatives used in inhibiting
                          PARP enzyme as therapeutic compounds
INVENTOR(S):              Helleday, Thomas; Curtin, Nicola
PATENT ASSIGNEE(S):       Cancer Research Technology Limited, UK
SOURCE:                   PCT Int. Appl., 58 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2005012305         A2    20050210    WO 2004-GB3183          20040723
     WO 2005012305         A3    20050407
```

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005143370	A1	20050630	US 2004-898653	20040723
PRIORITY APPLN. INFO.:			GB 2003-17466	A 20030725
			GB 2004-8524	A 20040416

AB The invention relates to tricyclic lactam indole derivs. and tricyclic lactam benzimidazole derivs. and their use in inhibiting the activity of PARP enzyme (poly(ADP-ribose)polymerase). The invention also relates to the use of these compds. in the preparation of medicaments for treatment of **cancer**.

L3 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	2004:857605 HCAPLUS
DOCUMENT NUMBER:	141:325793
TITLE:	Poly(ADP-ribose) polymerase (PARP) inhibitor 8-fluoro-2-(4-methylaminomethylphenyl)-1,3,4,5-tetrahydroazepino[5,4,3-cd]indol-6-one salts for therapeutic use
INVENTOR(S):	Canan-Koch, Stacie Sara; Chu, Jan-Jon; Liu, Jia; Matthews, Jean Joo
PATENT ASSIGNEE(S):	Pfizer Inc., USA
SOURCE:	PCT Int. Appl., 20 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087713	A1	20041014	WO 2004-IB915	20040319
WO 2004087713	C1	20050120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2520997	AA	20041014	CA 2004-2520997	20040319
EP 1611137	A1	20060104	EP 2004-721967	20040319

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

NL 1025842	A1	20041001	NL 2004-1025842	20040329
US 2004248879	A1	20041209	US 2004-811513	20040329
PRIORITY APPLN. INFO.:			US 2003-459433P	P 20030331
			WO 2004-IB915	W 20040319

AB Pharmaceutically acceptable salts of the title compound are PARP inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative

disease. As **cancer** therapeutics, the compds. of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation. Preparation of a variety of salts of the title compound is included.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2005:165945 USPATFULL

TITLE: Therapeutic compounds

INVENTOR(S): Helleday, Thomas, Stockholm, SWEDEN
Curtin, Nicola, Tyne and Wear, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005143370	A1	20050630
APPLICATION INFO.:	US 2004-898653	A1	20040723 (10)

App SN 10/898,653

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-17466	20030725
	GB 2004-8524	20040416

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: NOTARO AND MICHALOS, 100 DUTCH HILL ROAD, SUITE 110, ORANGEBURG, NY, 10962-2100, US

NUMBER OF CLAIMS: 32

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 8 Drawing Page(s)

LINE COUNT: 1303

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 7 USPATFULL on STN

ACCESSION NUMBER: 2005:99541 USPATFULL

TITLE: Tricyclic inhibitors of poly(ADP-ribose) polymerases

INVENTOR(S): Webber, Stephen Evan, San Diego, CA, UNITED STATES
Canan-Koch, Stacie S., La Jolla, CA, UNITED STATES
Tikhe, Jayashree, San Diego, CA, UNITED STATES
Thoresen, Lars Henrik, College Station, TX, UNITED STATES

PATENT ASSIGNEE(S): AGOURON PHARMACEUTICALS, INC. (U.S. corporation)
CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005085460	A1	20050421
	US 6977298	B2	20051220
APPLICATION INFO.:	US 2004-4261	A1	20041203 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-264018, filed on 2 Oct 2002, ABANDONED Continuation of Ser. No. US 2000-479896, filed on 10 Jan 2000, GRANTED, Pat. No. US 6495541

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115431P	19990111 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AGOURON PHARMACEUTICALS, INC., 10350 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037, US
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 2893
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. ##STR1## As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2004:315203 USPATFULL
TITLE: Salts of tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Canan-Koch, Stacie, La Jolla, CA, UNITED STATES
Chu, Jan-Jon, Carlsbad, CA, UNITED STATES
Liu, Jia, La Jolla, CA, UNITED STATES
Matthews, Jean, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004248879	A1	20041209	
APPLICATION INFO.:	US 2004-811513	A1	20040329	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-459433P	20030331 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AGOURON PHARMACEUTICALS, INC., 10350 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutically acceptable salts of compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2003:113513 USPATFULL
TITLE: Tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Webber, Stephen Evan, San Diego, CA, UNITED STATES
Canan-Koch, Stacie S., La Jolla, CA, UNITED STATES
Tikhe, Jayashree, San Diego, CA, UNITED STATES
Thoresen, Lars Henrik, College Station, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078254	A1	20030424

APPLICATION INFO.: US 2002-264018 A1 20021002 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-479896, filed on 10 Jan 2000, GRANTED, Pat. No. US 6495541

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115431P	19990111 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Agouron Pharmaceuticals, Inc., 10777 Science Center Road, San Diego, CA, 92121
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 3013
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. ##STR1##

As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2002:332731 USPATFULL
TITLE: Tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Webber, Stephen Evan, San Diego, CA, United States
Canan-Koch, Stacie S., La Jolla, CA, United States
Tikhe, Jayashree, San Diego, CA, United States
Thoresen, Lars Henrik, College Station, TX, United States
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495541	B1	20021217
APPLICATION INFO.:	US 2000-479896		20000110 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115431P	19990111 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Shanks & Herbert
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3029
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapuetics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and nuerodegenerative disease. ##STR1##

As **cancer** therapuetics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> s L3-L6
L8          7 (L3 OR L4 OR L5 OR L6)

=> dup rem
ENTER L# LIST OR (END):L8
PROCESSING COMPLETED FOR L8
L9           7 DUP REM L8 (0 DUPLICATES REMOVED)

=> d L8 ibib abs

L8   ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2005:120932  HCAPLUS
DOCUMENT NUMBER:         142:212321
TITLE:                   Tricyclic lactam indole derivatives and tricyclic
                         lactam benzimidazole derivatives used in inhibiting
                         PARP enzyme as therapeutic compounds
INVENTOR(S):             Helleday, Thomas; Curtin, Nicola
PATENT ASSIGNEE(S):      Cancer Research Technology Limited, UK
SOURCE:                  PCT Int. Appl., 58 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  2
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
     WO 2005012305        A2    20050210    WO 2004-GB3183           20040723
     WO 2005012305        A3    20050407
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     US 2005143370        A1    20050630    US 2004-898653           20040723
PRIORITY APPLN. INFO.:                      GB 2003-17466        A   20030725
                                            GB 2004-8524         A   20040416
AB   The invention relates to tricyclic lactam indole derivs. and tricyclic
     lactam benzimidazole derivs. and their use in inhibiting the activity of
     PARP enzyme (poly(ADP-ribose)polymerase). The invention also relates to
     the use of these compds. in the preparation of medicaments for treatment of
     cancer.


=> d L8 ibib abs 2-7

L8   ANSWER 2 OF 7  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2004:857605  HCAPLUS
DOCUMENT NUMBER:         141:325793
TITLE:                   Poly(ADP-ribose) polymerase (PARP) inhibitor
                         8-fluoro-2-(4-methylaminomethylphenyl)-1,3,4,5-
                         tetrahydroazepino[5,4,3-cd]indol-6-one salts for
                         therapeutic use
INVENTOR(S):             Canan-Koch, Stacie Sara; Chu, Jan-Jon; Liu, Jia;
                         Matthews, Jean Joo
PATENT ASSIGNEE(S):      Pfizer Inc., USA
```

SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087713	A1	20041014	WO 2004-IB915	20040319
WO 2004087713	C1	20050120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2520997	AA	20041014	CA 2004-2520997	20040319
EP 1611137	A1	20060104	EP 2004-721967	20040319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
NL 1025842	A1	20041001	NL 2004-1025842	20040329
US 2004248879	A1	20041209	US 2004-811513	20040329

PRIORITY APPLN. INFO.: US 2003-459433P P 20030331
WO 2004-IB915 W 20040319

AB Pharmaceutically acceptable salts of the title compound are PARP inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As **cancer** therapeutics, the compds. of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation. Preparation of a variety of salts of the title compound is included.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2005:165945 USPATFULL
TITLE: Therapeutic compounds
INVENTOR(S): Helleday, Thomas, Stockholm, SWEDEN
Curtin, Nicola, Tyne and Wear, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005143370	A1	20050630	
APPLICATION INFO.:	US 2004-898653	A1	20040723	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-17466	20030725
	GB 2004-8524	20040416

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NOTARO AND MICHALOS, 100 DUTCH HILL ROAD, SUITE 110, ORANGEBURG, NY, 10962-2100, US
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 1303
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2005:99541 USPATFULL
TITLE: Tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Webber, Stephen Evan, San Diego, CA, UNITED STATES
Canan-Koch, Stacie S., La Jolla, CA, UNITED STATES
Tikhe, Jayashree, San Diego, CA, UNITED STATES
Thoresen, Lars Henrik, College Station, TX, UNITED STATES
PATENT ASSIGNEE(S): AGOURON PHARMACEUTICALS, INC. (U.S. corporation)
CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005085460	A1	20050421
	US 6977298	B2	20051220
APPLICATION INFO.:	US 2004-4261	A1	20041203 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-264018, filed on 2 Oct 2002, ABANDONED Continuation of Ser. No. US 2000-479896, filed on 10 Jan 2000, GRANTED, Pat. No. US 6495541

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115431P	19990111 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AGOURON PHARMACEUTICALS, INC., 10350 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037, US
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 2893
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. ##STR1## As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2004:315203 USPATFULL
TITLE: Salts of tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Canan-Koch, Stacie, La Jolla, CA, UNITED STATES
Chu, Jan-Jon, Carlsbad, CA, UNITED STATES
Liu, Jia, La Jolla, CA, UNITED STATES
Matthews, Jean, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004248879	A1	20041209
APPLICATION INFO.:	US 2004-811513	A1	20040329 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-459433P	20030331 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AGOURON PHARMACEUTICALS, INC., 10350 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutically acceptable salts of compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2003:113513 USPATFULL
TITLE: Tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Webber, Stephen Evan, San Diego, CA, UNITED STATES
Canan-Koch, Stacie S., La Jolla, CA, UNITED STATES
Tikhe, Jayashree, San Diego, CA, UNITED STATES
Thoresen, Lars Henrik, College Station, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078254	A1	20030424
APPLICATION INFO.:	US 2002-264018	A1	20021002 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-479896, filed on 10 Jan 2000, GRANTED, Pat. No. US 6495541

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115431P	19990111 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Agouron Pharmaceuticals, Inc., 10777 Science Center Road, San Diego, CA, 92121
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
LINE COUNT: 3013
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. ##STR1##

As **cancer** therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 7 USPATFULL on STN
ACCESSION NUMBER: 2002:332731 USPATFULL
TITLE: Tricyclic inhibitors of poly(ADP-ribose) polymerases
INVENTOR(S): Webber, Stephen Evan, San Diego, CA, United States
Canan-Koch, Stacie S., La Jolla, CA, United States

Tikhe, Jayashree, San Diego, CA, United States
Thoresen, Lars Henrik, College Station, TX, United States
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495541	B1	20021217
APPLICATION INFO.:	US 2000-479896		20000110 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-115431P	19990111 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Kifle, Bruck
LEGAL REPRESENTATIVE: Shanks & Herbert
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 3029
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapuetics in treatment of **cancers** and the amelioration of the effects of stroke, head trauma, and nuerodegenerative disease. ##STR1##

As **cancer** therapuetics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 17:44:04 ON 26 JAN 2006)

FILE 'REGISTRY' ENTERED AT 17:44:44 ON 26 JAN 2006
L1 1 S 283173-50-2/RN

FILE 'HCAPLUS, USPATFULL' ENTERED AT 17:45:32 ON 26 JAN 2006
L2 8 S L1
L3 7 S L2 AND CANCER
L4 1 S L3 AND IRENOTECAN
L5 1 S L3 AND TEMOZOLAMIDE
L6 2 S L3 AND DACARBAZINE
L7 7 DUP REM L3 (0 DUPLICATES REMOVED)
L8 7 S L3-L6
L9 7 DUP REM L8 (0 DUPLICATES REMOVED)